Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease

Author(s): Carlo Wilke, Frank Gillardon, Christian Deuschle, Evelyn Dubois, Markus A. Hobert, Jennifer Müller vom Hagen, Stefanie Krüger, Saskia Biskup, Cornelis Blauwendraat, Michael Hruscha, Stephan A. Kaeser, Peter Heutink, Walter Maetzler, Matthis Synofzik.

Journal Name: Current Alzheimer Research

Volume 13 , Issue 6 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer’s dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations. Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin levels and their response to future progranulin-increasing therapeutics.

Keywords: Alzheimer’s dementia, amyotrophic lateral sclerosis, biomarker, case-control study, cerebrospinal fluid, frontotemporal dementia, GRN, progranulin, serum.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 6
Year: 2016
Page: [654 - 662]
Pages: 9
DOI: 10.2174/1567205013666160314151247
Price: $58

Article Metrics

PDF: 29
HTML: 3
EPUB: 1
PRC: 1